Imugene Investor Relations Material
Latest events
Investor Update
Imugene
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Imugene Limited
Access all reports
Imugene Limited is an Australian biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered around activating the immune system to target and eliminate cancer cells, utilizing a range of technologies, including oncolytic viruses and B-cell activating immunotherapies. Imugene’s clinical pipeline includes treatments for various cancer types, and the company works on advancing its therapies through preclinical and clinical development stages. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.
Key slides for Imugene Limited
AGM 2024
Imugene Limited
AGM 2024
Imugene Limited
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IMU
Country
🇦🇺 Australia